Poolbeg Pharma treatment gets FDA backing
The treatment, named POLB 001, is an oral preventative therapy to treat inflammation in blood and tissues. CRS is a severe side-effect that occurs in more than 70 per cent of patients, leading to severe side-effects or death.
Cytokines can sweep throughout the body and cause tissue damage and shut down circulation and other essential organs.
Orphan status is granted by the FDA for to support the development of treatments for rare disorders that affect under 200,000 people in the US, and makes the development of the drug less risky for Poolbeg, with the potential for seven-year period of US market exclusivity following approval of the treatment, waiver exemption of some fees and tax credits for qualified clinical trials.
READ MORE
'POLB 001 is potentially a breakthrough, orally delivered, preventative therapy for cancer immunotherapy-induced CRS which could significantly impact patients' lives,' said Poolbeg chief executive Jeremy Skillington.
'We were delighted to receive Orphan Drug Designation from the FDA, which is a significant development for Poolbeg and for POLB 001, one that we believe will enhance the commercial appeal for prospective partners and help bring POLB 001 to the market faster. If approved, we believe POLB 001 has the potential to improve quality of life for patients, reduce pressure on healthcare systems, and expand access to cancer immunotherapies.'
There are currently no approved preventative therapies for CRS. The first patients are expected to get the drug in the second half of the year, as part of Poolbeg's Phase 2a trial.
'Orphan Drug Designation from the FDA underscores the urgency and importance of developing innovative therapies for this critical unmet medical need,' said Professor Brendan Buckley, Poolbeg non-executive director and a member of the scientific advisory board.
'We look forward to progressing POLB 001 in our upcoming Phase 2a clinical trial and working closely with prospective partners and regulatory agencies to bring this potential therapy to patients as quickly as possible.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Times
12 hours ago
- Irish Times
Zuckerberg's ‘mercenary' AI binge is paying off on Wall Street
Meta 's gigantic AI spending is being handsomely rewarded by investors. The stock soared after its latest earnings beat and is now up 30 per cent in 2025, pushing Meta's market value close to $2 trillion. After being punished for Mark Zuckerberg 's extravagant bet on the metaverse – remember that? – investors are showing a more forgiving streak, perhaps because AI's pay-off looks more tangible. Meta is expected to spend up to $72 billion on AI infrastructure this year. Next year's bill may top $100 billion. Some engineers reportedly command salaries of more than $100 million, underscoring the scale of Meta's ambitions. Such lavish outlays have raised eyebrows – OpenAI's Sam Altman called Meta's conduct 'distasteful', telling staff that 'missionaries will beat mercenaries'. READ MORE Not that Zuckerberg is averse to missionary talk himself. He describes AI as a path to 'personal superintelligence' that will help users 'experience any adventure, be a better friend' and 'become the person you aspire to be' – presumably after clicking a few more ads. It's the ads investors care about. AI is seemingly juicing Meta's core business, driving user engagement and ad revenue through smarter targeting and tools. This enthusiasm isn't limited to Meta. Google and Microsoft shares have also rallied, as markets reward big AI bets. Sceptics see froth, but while Meta shares are up nearly 50 per cent year on year, the valuation – 27.5 times estimated earnings – remains relatively grounded. The rally looks driven more by fundamentals than hype. Memories of the metaverse linger, but this time, investors believe Zuckerberg's spending will deliver.
Irish Times
13 hours ago
- Irish Times
Apple needs to up its game to impress
What does Apple have to do to impress analysts? A lot more than it is currently doing, it seems. Despite delivering a healthy set of results for its third quarter, investors seem to be unimpressed. The iPhone maker reported revenue that rose almost 10 per cent to $94 billion (€81.4 billion), with strong sales of its smartphones and momentum in China. But that wasn't enough to convince analysts that the company is on the right track. The bump in device sales was being viewed in some quarters as a reaction to potential tariffs, with lingering worries over what Donald Trump's trade war will do to Apple's future prospects. Meanwhile, the tech giant seems to be slipping further and further behind its rivals when it comes to the buzziest technology of them all: artificial intelligence . READ MORE Just over a year after the company unveiled its plans for Apple Intelligence, the speculation that Apple has lost its edge and its innovation is still rife. The tech giant has been slow to roll out new features, adopting a cautious approach to the technology even as Google and Samsung plough ahead. One of the biggest blows was the news that Apple was delaying the AI-powered, smarter version of Siri that it had previously promised. [ Is it time for a new kind of CEO at Apple? Opens in new window ] Apple has a tough line to walk. It has built its reputation on protecting the privacy of its customers, and views any developments in this area through that lens. And that means evaluating the potential impact of every decision on consumer privacy. But on Friday morning the company's shares dipped lower, extending a negative run for Apple that has seen the company's shares lose almost 17 per cent in the year to date. In contrast, one-time rival Microsoft has gained 25 per cent since the start of 2025, and Google parent company Alphabet is largely flat. Apple may have a plan up its sleeve. Chief executive Tim Cook indicated that he was open to the possibility of a deal with AI companies to help advance the technology on its platform. But that may not be enough to keep investors happy.
Irish Times
13 hours ago
- Irish Times
Court case to overturn ‘fraudulent' Seán Dunne transfers played key part in US bankruptcy
Seán Dunne's US bankruptcy trustee realised $20.9 million (€18.1 million) from the 'fraudulent conveyance' claim he took in the US courts while overseeing the estate of the high-profile Irish property developer, according to a new document filed to a court in Connecticut. With the gross receipts realised by Richard Coan coming to $27.5 million, the successful case taken against Mr Dunne in the US courts accounted for a large proportion of what was available for his unfortunate creditors. Mr Coan has now filed his final report to the bankruptcy court in Connecticut at the end of a process that began in 2013 and involved legal and other manoeuvres on both sides of the Atlantic as Mr Dunne ducked and dived with not one but two bankruptcies involving hundreds of millions of euro in debts to banks. His assets, as Mr Coan's final report indicates, were a lot more modest than those debts, so much so that the €14 million secured in 2013 from the sale of Walford, a house on Shrewsbury Road, Ballsbridge, Dublin 4, that Mr Dunne and his then wife, Gayle Killilea , bought for €58 million eight years earlier, was a big part of what remained of his wealth. READ MORE In 2019, a jury in the district court in Connecticut found in favour of Mr Coan, who took a case alleging Mr Dunne had fraudulently transferred assets worth millions of dollars to Ms Killilea. Among the transfers complained of was proceeds from the sale of Walford. To fund the lawyers who acted for the US trustee in his battles with Mr Dunne, Nama and Ulster Bank issued non-interest bearing loans to pay the legal fees. Meanwhile, on this side of the Atlantic, where Mr Dunne's bankruptcy status has been extended to 2028 due to his non-cooperation with the Official Assignee, a series of legal proceedings continues. Mr Dunne has taken a number of so far unsuccessful cases against those overseeing his bankruptcy estate. The final report now filed by Mr Coan with the Connecticut court includes detailed records on recent legal bills amassed by law firm Cohn Birnbaum & Shea, engaged by Mr Coan in 2022, to work with him on the Dunne case. Fees charged by the firm amounted to between $355 and $475 an hour for a partner, and $210 to $250 for a paralegal. Records show many phone calls, reviews and email communications, and the times spent on them, as the trustee's lawyers dealt with various claims. These included claims from Ms Killilea and from Mr Dunne's first wife, Jennifer Coyle, contacts with a wide range of parties including the Revenue Commissioners and work on keeping abreast on what was happening in Ireland. Discussion and analysis of the 'priority claims' of Ms Killilea and of Ms Coyle were the subject of numerous calls and reviews that continued into this year as were matters to do with claims from banks. In the end, the priority claims agreed were $925,306 for Ms Killilea and were $1,948,764 for Ms Coyle, leaving a balance of $12.38 million. The bulk of that was shared between Nama, which got $6 million on a claim of $438 million, and Ulster Bank, which also got $6 million on its claim of $428 million. Meanwhile, the legal wrangling continues in the High Court in Dublin.
